News articles about ImmuCell Corporation (NASDAQ:ICCC) have trended somewhat positive this week, Accern reports. The research firm scores the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. ImmuCell Corporation earned a news impact score of 0.13 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 46.4477194738328 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

ImmuCell Corporation (NASDAQ:ICCC) traded up 5.34% during mid-day trading on Friday, hitting $6.12. 1,527 shares of the stock were exchanged. The firm has a 50-day moving average price of $6.67 and a 200-day moving average price of $6.11. ImmuCell Corporation has a 12-month low of $4.76 and a 12-month high of $8.24. The stock has a market capitalization of $30.89 million, a P/E ratio of 70.34 and a beta of 1.02.

ImmuCell Corporation (NASDAQ:ICCC) last issued its quarterly earnings data on Monday, August 14th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter. ImmuCell Corporation had a net margin of 4.55% and a return on equity of 2.25%. The business had revenue of $1.75 million during the quarter.

Separately, TheStreet raised shares of ImmuCell Corporation from a “c” rating to a “b-” rating in a research report on Monday, June 12th.

COPYRIGHT VIOLATION WARNING: This article was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another domain, it was stolen and republished in violation of U.S. & international copyright and trademark laws. The original version of this article can be accessed at

In other news, insider Brian L. Pessin bought 30,000 shares of the business’s stock in a transaction on Thursday, July 27th. The shares were purchased at an average price of $5.25 per share, for a total transaction of $157,500.00. Following the purchase, the insider now owns 70,000 shares of the company’s stock, valued at approximately $367,500. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. 20.10% of the stock is currently owned by insiders.

About ImmuCell Corporation

ImmuCell Corporation is an animal health company. The Company operates in the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries segment. The Company has developed products that provide immediate immunity to newborn dairy and beef cattle, and is developing product line extensions of its existing products that address mastitis.

Insider Buying and Selling by Quarter for ImmuCell Corporation (NASDAQ:ICCC)

Receive News & Stock Ratings for ImmuCell Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuCell Corporation and related stocks with our FREE daily email newsletter.